Adaptive Therapy and the Cost of Drug-Resistant Mutants

Area of Science:

• Oncology
• Mathematical Biology
• Cancer Therapeutics

Background:

• Adaptive cancer therapy uses sub-lethal drug doses to delay tumor progression.
• This strategy relies on drug-sensitive cells outcompeting drug-resistant cells.
• Previous models assumed resistant cells have a fitness disadvantage.

Purpose of the Study:

• To investigate the efficacy of adaptive cancer therapy without a fitness cost for resistant cells.
• To broaden the applicability of adaptive therapy strategies.
• To explore mathematical models of cancer treatment dynamics.

Main Methods:

• Mathematical modeling of tumor cell dynamics under adaptive therapy.
• Analysis of conditions for clinical benefit in adaptive cancer therapy.
• Simulation of tumor evolution with and without resistant cell fitness costs.

Main Results:

• Adaptive therapy can provide clinical benefits even when resistant cells do not have a fitness cost.
• The competitive suppression of resistant cells by sensitive cells is key.
• This finding expands the potential use of adaptive therapy in diverse cancer types.

Conclusions:

• Adaptive cancer therapy is a viable strategy that can be effective without requiring a fitness cost in resistant cells.
• The findings broaden the theoretical and practical applications of adaptive therapy.
• Further clinical trials are warranted to explore this refined adaptive therapy approach.